cyclosporine + mycophenolate mofetil

This entry refers to a comparative clinical study (NCT00295425) conducted by the University Hospital Muenster evaluating the efficacy and safety of two systemic immunosuppressants, cyclosporine A and mycophenolate mofetil, in patients with moderate-to-severe chronic plaque-type psoriasis. Cyclosporine A is a small molecule calcineurin inhibitor that prevents T-cell activation by binding to cyclophilin and subsequently inhibiting the phosphatase activity of calcineurin. Mycophenolate mofetil is a small molecule prodrug of mycophenolic acid that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), leading to the depletion of guanosine nucleotides and selective inhibition of T- and B-lymphocyte proliferation. The trial randomized 54 patients to receive either cyclosporine A (2.5 mg/kg) or mycophenolate mofetil (2 g daily), finding that cyclosporine A demonstrated significantly superior efficacy in achieving PASI score reductions over a 12-week treatment period.

Brand names

CellCeptNeoralSandimmune

Other names

cyclosporine a versus mycophenolate mofetil-University Hospital Muenster-psoriasisMycophenolate Mofetil vs Cyclosporine A for Moderate-Severe Psoriasis